BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11528457)

  • 1. Achilles' heel of cancer?
    Vogelstein B; Kinzler KW
    Nature; 2001 Aug; 412(6850):865-6. PubMed ID: 11528457
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.
    Chène P
    Nat Rev Cancer; 2003 Feb; 3(2):102-9. PubMed ID: 12563309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploiting the p53 pathway for cancer diagnosis and therapy.
    Lane DP
    Br J Cancer; 1999 Jul; 80 Suppl 1():1-5. PubMed ID: 10466753
    [No Abstract]   [Full Text] [Related]  

  • 4. Methods for screening tumors for p53 status and therapeutic exploitation.
    Tullo A; D'Erchia AM; Sbisà E
    Expert Rev Mol Diagn; 2003 May; 3(3):289-301. PubMed ID: 12779005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Turning the key on p53.
    Lane DP; Fischer PM
    Nature; 2004 Feb; 427(6977):789-90. PubMed ID: 14985740
    [No Abstract]   [Full Text] [Related]  

  • 6. p53: upstream, downstream and off stream. Review of the 8th p53 workshop (Dundee, July 5-9, 1996).
    Oren M; Prives C
    Biochim Biophys Acta; 1996 Dec; 1288(3):R13-9. PubMed ID: 9011182
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
    Chène P
    Mol Cancer Res; 2004 Jan; 2(1):20-8. PubMed ID: 14757842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Progress of p53 gene].
    Xu SF; Fu L
    Zhonghua Bing Li Xue Za Zhi; 2004 Dec; 33(6):559-61. PubMed ID: 15634457
    [No Abstract]   [Full Text] [Related]  

  • 9. Regulation of p53 function.
    Woods DB; Vousden KH
    Exp Cell Res; 2001 Mar; 264(1):56-66. PubMed ID: 11237523
    [No Abstract]   [Full Text] [Related]  

  • 10. Cancer research. Drug candidate bolsters cell's tumor defenses.
    Marx J
    Science; 2004 Jan; 303(5654):23-5. PubMed ID: 14704399
    [No Abstract]   [Full Text] [Related]  

  • 11. Activation and activities of the p53 tumour suppressor protein.
    Bálint E E; Vousden KH
    Br J Cancer; 2001 Dec; 85(12):1813-23. PubMed ID: 11747320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
    Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
    Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of p14ARF overcomes tumor resistance to p53.
    Lu W; Lin J; Chen J
    Cancer Res; 2002 Mar; 62(5):1305-10. PubMed ID: 11888896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer drug discovery: the wisdom of imprecision.
    Gudkov AV
    Nat Med; 2004 Dec; 10(12):1298-9. PubMed ID: 15580251
    [No Abstract]   [Full Text] [Related]  

  • 15. P53 and prognosis: new insights and further complexity.
    Vousden KH; Prives C
    Cell; 2005 Jan; 120(1):7-10. PubMed ID: 15652475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Facilitation of adenoviral wild-type p53-induced apoptotic cell death by overexpression of p33(ING1) in T.Tn human esophageal carcinoma cells.
    Shimada H; Liu TL; Ochiai T; Shimizu T; Haupt Y; Hamada H; Abe T; Oka M; Takiguchi M; Hiwasa T
    Oncogene; 2002 Feb; 21(8):1208-16. PubMed ID: 11850840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug discovery and p53.
    Lane DP; Hupp TR
    Drug Discov Today; 2003 Apr; 8(8):347-55. PubMed ID: 12681938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and Rb.
    Ameyar M; Shatrov V; Bouquet C; Capoulade C; Cai Z; Stancou R; Badie C; Haddada H; Chouaib S
    Oncogene; 1999 Sep; 18(39):5464-72. PubMed ID: 10498900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression.
    Meng RD; Shih H; Prabhu NS; George DL; el-Deiry WS
    Clin Cancer Res; 1998 Jan; 4(1):251-9. PubMed ID: 9516979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to p53-mediated growth suppression in human ovarian cancer cells retain endogenous wild-type p53.
    Jin X; Burke W; Rothman K; Lin J
    Anticancer Res; 2002; 22(2A):659-64. PubMed ID: 12014634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.